Article Text

Download PDFPDF

Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida
  1. M S Lungarotti,
  2. D Mezzetti,
  3. M Radicioni
  1. Policlinico Monteluce, Via Brunamonti, Perugia, PG 06100, Italy; dm2{at}

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Saccharomyces boulardii is closely related to Saccharomyces cerevisiae and is used as biotherapeutic agent,1 although some reports suggest pathogenicity.2 We present a case of neonatal fungaemia with concurrent methaemoglobinaemia, occurring after a brief period of treatment with S boulardii. A male infant was born at 30 weeks of gestational age by caesarean section because of intrauterine growth restriction and maternal hypertension. The baby was well apart from persistent gastrointestinal symptoms that hampered feeding and forced parenteral support. During the third week of life, administration of S boulardii (Codex DNB; half a capsule a day, equivalent to 2.5 × 109 organisms) was started in an attempt to prevent bacterial overgrowth. After four days of treatment, the baby developed symptoms suggesting sepsis and an unexplained methaemoglobinaemia (methaemoglobin concentration = 16%). Codex was stopped and empirical antibiotic coverage, including liposomal amphotericin B, was started. Blood cultures showed growth of Candida albicans, but the central venous catheter tip was negative. Methaemoglobin levels halved in two days (7%), but remained constant during the following two weeks of antifungal treatment. Blood cultures at that point showed growth of S cerevisiae, which is susceptible to amphotericin B, in the absence of any clinical finding; again, the catheter tip was sterile. Methaemoglobin concentration was still abnormal (6.2%). Liposomal amphotericin B treatment was prolonged for a further six days and then discontinued. At this time, methaemoglobin levels were near normal (3%), and blood cultures were negative. The gastrointestinal symptoms resolved with age and full gastrointestinal function was achieved.

    Recovery of Saccharomyces two weeks after administration had been stopped suggests persistence in the gut. It is tempting to think that the methaemoglobinaemia was caused by the continued presence of the yeasts, perhaps through excessive host production of nitric oxide. Several studies have shown that nitric oxide plays a pivotal role in the interaction between yeasts and the phagocytic system,3 and it is well known that this radical readily oxidises haemoglobin. It is also reasonable to link late bloodstream invasion by Saccharomyces to previous enteric mucosal damage caused by a Candida infection, which was itself probably gut related. The recovery of S cerevisiae in place of S boulardii has been reported by others,4 and can be explained by the similarities between the two. It is ironic that the intervention used to prevent sepsis from enteric overgrowth not only did not succeed but was itself a cause of the problem that it was intended to prevent.